Credit: Getty Images Experts weigh in on the ramifications of GLP-1 drug shortages and how they affect patients who need these medications for the management of diabetes. With the ongoing surge in ...

Related Wegovy, other weight-loss drugs might help with alcoholism, opioid addiction Weight-loss drugs can help stroke survivors prevent recurrence Weight-loss surgeries decline 25% as GLP-1 drugs ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

In the univariate analysis, those on an SGLT-2i/GLP-1 RA had a reduced risk for mortality, incident MI, and composite. (HealthDay News) — For patients with ischemic stroke, sodium-glucose ...

In addition to ensuring equitable access to the glucagon-like peptide-1 (GLP-1) receptor agonists, the medical community needs to figure out how to keep patients on the drugs long term to fully ...

PHILADELPHIA — New research provides more evidence that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) do not increase the risk for pancreatic cancer. Instead, the large electronic health ...

HERSHEY, PA. — GLP-1 weight-loss drugs are having a “mild impact” on The Hershey Co.’s business, president and chief executive officer Michele Buck told analysts in a conference call on ...

Subhani's team focused at results from six studies conducted before August of this year, including two "gold standard" clinical trials comprising a total of more than 88,000 people, about 44% of who ...

About The Article: This Viewpoint discusses the health benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs); summarizes the clinical, policy, and equity implications of GLP-1 RA ...

GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective treatment options for obesity. Medications such as semaglutide (branded as Ozempic ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...